Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
  1. Home
  2. Publications
  3. Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Authors:
  • MRMilan Radovich
    Milan Radovich
  • JSJeffrey P. Solzak
    Jeffrey P. Solzak
  • CWChao J. Wang
    Chao J. Wang
  • BHBradley A. Hancock
    Bradley A. Hancock
  • Sunil Badve
    Sunil Badve
  • SASandra K. Althouse
    Sandra K. Althouse
  • SBSteven M. Bray
    Steven M. Bray
  • ASAnna Maria V. Storniolo
    Anna Maria V. Storniolo
  • TBTarah J. Ballinger
    Tarah J. Ballinger
  • BSBryan P. Schneider
    Bryan P. Schneider
  • KMKathy D. Miller
    Kathy D. Miller

Open Access
Publisher website
Google Scholar
  • 31 March 2023
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.22487393.v1
Abstract
Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Keywords
  • INITIAL PHASE
  • PHASE I SAFETY
  • FIGURE FROM INITIAL
  • SUPPLEMENTARY FIGURE
  • COFETUZUMAB
  • GEDATOLISIB
  • METASTATIC
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.